Cornerstone Wealth Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$266K Buy
+3,793
New +$196K 0.01% 643
2024
Q2
Sell
-2,537
Closed -$270K 563
2024
Q1
$270K Sell
2,537
-280
-10% -$28.2K 0.02% 447
2023
Q4
$280K Buy
2,817
+4
+0.1% +$336 0.02% 424
2023
Q3
$291K Sell
2,813
-149
-5% -$16.6K 0.03% 424
2023
Q2
$360K Sell
2,962
-599
-17% -$79.9K 0.03% 365
2023
Q1
$547K Buy
+3,561
New +$587K 0.05% 273
2022
Q3
$346K Hold
2,923
0.04% 321
2022
Q2
$418K Buy
2,923
+73
+3% +$10.4K 0.05% 296
2022
Q1
$491K Sell
2,850
-465
-14% -$78.3K 0.05% 276
2021
Q4
$841K Sell
3,315
-150
-4% -$43.9K 0.08% 204
2021
Q3
$1.33M Buy
3,465
+950
+38% +$350K 0.14% 148
2021
Q2
$591K Sell
2,515
-111
-4% -$19.8K 0.06% 260
2021
Q1
$344K Buy
+2,626
New +$381K 0.04% 333

Other funds holding MRNA

Cornerstone Wealth Management's MRNA Position: Q2 2026 in Review

Cornerstone Wealth Management opened a new position in Moderna (MRNA) in Q2 2026: 3,793 shares worth $266K. The stake represents 0.01% of the portfolio and ranks #643 among its holdings. This is a return to the name: Cornerstone Wealth Management previously reported a position in MRNA as recently as Q1 2024.

Cornerstone Wealth Management first reported a position in MRNA in Q1 2021 and has held it in 13 quarters since. The position peaked at $1.33M in Q3 2021. 154 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Cornerstone Wealth Management held 3,793 shares of Moderna worth $266K as of Q2 2026.
  • Moderna was a new Cornerstone Wealth Management position in Q2 2026.
  • Moderna made up 0.01% of Cornerstone Wealth Management's portfolio in Q2 2026, its #643 holding.
  • Cornerstone Wealth Management first reported a position in Moderna in Q1 2021 and has held it in 13 quarters since.
  • Cornerstone Wealth Management's Moderna position peaked at $1.33M in Q3 2021.
  • 154 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Cornerstone Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.